Intravenous lipid emulsion does not reverse dabigatran-induced anticoagulation in a rat model

Academic Emergency Medicine

Volumn 20, Issue 10, 2013, Pages 1022-1025

  Blum, Jared ^a   Carreiro, Stephanie ^a   Hack, Jason B ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN; LIPID EMULSION; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANTICOAGULATION; ARTICLE; BLEEDING TIME; BLOOD SAMPLING; CONTROLLED STUDY; DRUG EFFECT; NONHUMAN; PRIORITY JOURNAL; RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTITHROMBINS; BENZIMIDAZOLES; BETA-ALANINE; BLEEDING TIME; BLOOD COAGULATION; FAT EMULSIONS, INTRAVENOUS; HEMORRHAGE; MALE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84886935158     PISSN: 10696563     EISSN: 15532712     Source Type: Journal    
DOI: 10.1111/acem.12225     Document Type: Article

References (26)

1. U.S. Food & Drug Administration. FDA Approves Pradaxa to Prevent Stroke in People With Atrial Fibrillation. Available at: http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/ucm230241.htm. Accessed Jul 27, 2013.
2. Kannel WB, Benjamin EJ,. Status of the epidemiology of atrial fibrillation. Med Clin North Am. 2008; 92: 17-40.
3. Connolly S, Ezekowitz D, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361: 1139-51.
4. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010; 103: 1116-27.
5. Battinelli EM,. Reversal of new oral anticoagulants. Circulation. 2011; 124: 1508-10.
6. Augoustides JG,. Advances in anticoagulation: focus on dabigatran, an oral direct thrombin inhibitor. J Cardiothorac Vasc Anesth. 2011; 25: 1208-12.
7. Stangier J, Clemens A,. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost. 2009; 15: 9S-16S.
8. Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogne JM,. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost. 2012; 107: 985-97.
9. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M,. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011; 124: 1573-9.
10. Zhou W, Schwarting S, Illances S, et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke. 2011; 42: 3594-9.
11. Cave G, Harvey M,. Intravenous lipid emulsion as antidote beyond local anesthetic toxicity: a systematic review. Acad Emerg Med. 2009; 16: 815-24.
12. Weinberg GL, VadeBoncouer T, Ramaraju GA, Garcia-Amaro MF, Cwik MJ,. Pretreatment or resuscitation with a lipid infusion shifts the dose-response to bupivacaine-induced asystole in rats. Anesthesiology. 1998; 88: 1071-5.
13. Harvey MG, Cave GR,. Intralipid infusion ameliorates propranolol-induced hypotension in rabbits. J Med Toxicol. 2008; 4: 71-6.
14. Rothschild L, Bern S, Oswald S, Weinberg G,. Intravenous lipid emulsion in clinical toxicology. Scand J Trauma Resusc Emerg Med. 2010; 18: 51.
15. Picard J, Ward SC, Zumpe R, Meek T, Barlow J, Harrop-Griffiths W,. Guidelines and the adoption of 'lipid rescue' therapy for local anaesthetic toxicity. Anaesthesia. 2009; 64: 122-5.
16. Neal JM, Bernards CM, Butterworth JF, et al. ASRA Practice advisory on local anesthetic systemic toxicity. Reg Anesth Pain Med. 2010; 35: 152-61.
17. Niiya T, Litonius E, Petäjä L, Neuvonen PJ, Rosenberg PH,. Intravenous lipid emulsion sequesters amiodarone in plasma and eliminates its hypotensive action in pigs. Ann Emerg Med. 2010; 56: 402-8.
18. Turner-Lawrence DE, Kerns W II,. Intravenous fat emulsion: a potential novel antidote. J Med Toxicol. 2008; 4: 109-14.
19. Mazoit JX, Le Guen R, Beloeil H, Benhamou D,. Binding of long-lasting local anesthetics to lipid emulsions. Anesthesiology. 2009; 110: 380-6.
20. Rautio J, (ed.). Prodrugs and Targeted Delivery. Weinheim, Germany: Wiley-VCH, 2011.
21. French D, Smollin C, Raun W, Wong A, Drasner K, Wu AH,. Partition constant and volume of distribution as predictors of clinical efficacy of lipid rescue for toxicological emergencies. Clin Toxicol (Phila). 2011; 49: 801-9.
22. Castanares-Zapatero D, Wittebole X, Huberlant V, Morunglav M, Hantson P,. Lipid emulsion as rescue therapy in lamotrigine overdose. J Emerg Med. 2012; 42: 48-51.
23. Sirianni AJ, Osterhoudt KC, Calello DP, et al. Use of lipid emulsion in the resuscitation of a patient with prolonged cardiovascular collapse after overdose of bupropion and lamotrigine. Ann Emerg Med. 2008; 51: 412-5.
24. Wienen W, Stassen JM, Priepke H, Ries UJ, Hauel N,. Effects of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, on thrombus formation and bleeding time in rats. Thromb Haemost. 2007; 98: 333-8.
25. Perez E, Bania TC, Medlej K, Chu J,. Determining the optimal dose of intravenous fat emulsion for the treatment of severe verapamil toxicity in a rodent model. Acad Emerg Med. 2008; 15: 1284-9.
26. Cave G, Harvey MG, Castle CD,. The role of fat emulsion therapy in a rodent model of propranolol toxicity: a preliminary study. J Med Toxicol. 2006; 2: 4-7.